WO2023139106 - LONG-ACTING GIPR ANTAGONISTS
National phase entry is expected:
Publication Number
WO/2023/139106
Publication Date
27.07.2023
International Application No.
PCT/EP2023/051098
International Filing Date
18.01.2023
Title **
[English]
LONG-ACTING GIPR ANTAGONISTS
[French]
ANTAGONISTES DE GIPR À LONGUE DURÉE D'ACTION
Applicants **
NOVO NORDISK A/S
Novo Allé
2880 Bagsværd, DK
Inventors
FINAN, Brian Patrick
5225 Exploration Drive
Indianapolis, Indiana 46241, US
YANG, Bin Shubin
5225 Exploration Drive
Indianapolis, Indiana 46241, US
Priority Data
63/300,461
18.01.2022
US
22155553.5
08.02.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1679 | |
| EPO | Filing, Examination | 7790 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 7910 |
Total: 18575 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present application relates to novel peptides that are derivatives of glucose-dependent insulinotropic peptide (GIP) analogues with improved GIP antagonistic activity, and to the pharmaceutical use of the GIP derivatives. The GIP derivatives of the invention are modified by including a lipophilic moiety.[French]
La présente demande concerne de nouveaux peptides qui sont des dérivés d'analogues de peptide insulinotrope dépendant du glucose (GIP) ayant une activité antagoniste de GIP améliorée, et l'utilisation pharmaceutique des dérivés de GIP. Les dérivés de GIP de l'invention sont modifiés en incluant une fraction lipophile.